Skip to content


Deucravacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against non-receptor tyrosine-protein kinase TYK2. In addition, it is known to target tyrosine-protein kinase JAK1 and bone morphogenetic protein receptor type-2.
Trade Name
Common Name Deucravacitinib
Drug Class Tyrosine kinase inhibitors: janus kinase inhibitors; deuterated compounds
Get full access now